Status:
COMPLETED
Chronic HBV Management for Asian American
Lead Sponsor:
Temple University
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Hepatitis B, Chronic
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
About 75% of liver cancers are attributed to chronic hepatitis B (CHB). An estimated 2.2 million individuals in the U.S. have CHB. Although Asian Americans make up 6% of total U.S. population, they ac...
Detailed Description
Liver cancer is the second-leading cause of cancer deaths worldwide, which increased at the highest rate of all cancers in the U.S between 2003 and 2012. Asian Americans have the highest incidence and...
Eligibility Criteria
Inclusion
- 1\. Age 18 and above
- 2\. Self-identified Chinese, Korean or Vietnamese ethnicity
- 3\. Chronic HBV infection with positive HBV surface antigen (HBsAg)
- 4\. Non-compliant to HBV monitoring and treatment guidelines
Exclusion
- \-
Key Trial Info
Start Date :
April 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
382 Patients enrolled
Trial Details
Trial ID
NCT04082338
Start Date
April 1 2019
End Date
March 31 2022
Last Update
June 22 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychology, Hunter College
New York, New York, United States, 10065
2
Center for Asian Health, Lewis Katz School of Medicine, Temple University
Philadelphia, Pennsylvania, United States, 19140